Dr. Elyse Watkins
Type 2 diabetes mellitus is a common chronic condition managed by primary care providers. Therapeutic glucose control can reduce the risk of diabetes complications, including cardiovascular disease, neuropathy, nephropathy, and retinopathy. Previously, glucose self-assessment was primarily completed using blood glucose monitoring with intermittent measurements of hemoglobin A1c. The emergence of continuous glucose monitoring (CGM) has become an increasingly accessible, affordable, and convenient option for patients and clinicians to quantify glycemic control. Historically, CGM was reserved for patients with type 1 diabetes, but its use has expanded to patients with type 2 diabetes, particularly for those managed with insulin injections. CGM is an innovative tool to assess glycemic control and provide real-time feedback. Several studies have demonstrated that CGM improves glycemic control and reduces the risk of hypoglycemia. CGM should be considered for patients with type 2 diabetes mellitus who take insulin or are at risk for hypoglycemia. Clinicians can understand and utilize the data from CGM to make clinical decisions regarding type 2 diabetes mellitus treatment.
Bindner SA. Continuous Glucose Monitoring in Type 2 Diabetes Mellitus. Lynchburg Journal of Medical Science. 2023; 5(1).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.